These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21729522)

  • 21. Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia.
    Oka S; Muroi K; Matsuyama T; Sato K; Ueda M; Toshima M; Suzuki T; Ozaki K; Mori M; Takubo T; Nagai T; Hanafusa T; Ozawa K
    Hematology; 2009 Jun; 14(3):133-8. PubMed ID: 19490757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach.
    Yang C; Wang Y; Ge MH; Fu YJ; Hao R; Islam K; Huang P; Chen F; Sun J; Hong F; Naranmandura H
    Biomater Sci; 2019 Feb; 7(3):938-950. PubMed ID: 30519686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
    Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
    Aoyama Y; Yamane T; Kanashima H; Takeoka Y; Koh K; Nakao Y; Yamamura R; Nakamae H; Ohta K; Inoue T; Hino M; Tatsumi N
    Rinsho Ketsueki; 2001 Apr; 42(4):314-20. PubMed ID: 11400303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
    Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
    Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
    Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
    Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
    Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
    Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
    Bae J; Martinson JA; Klingemann HG
    Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
    Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells.
    Takeshita A; Shinjo K; Ohnishi K; Ohno R
    Br J Haematol; 1996 Apr; 93(1):18-21. PubMed ID: 8611458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical and laboratory study on acute myeloid leukemia with t(6;9)(p23;q34)].
    Wang Y; Xue Y; Chen S; Wu Y; Pan J; Zhang J; Shen J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):34-7. PubMed ID: 20140864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
    Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
    Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens.
    Le Dieu R; Taussig D; Lister TA; Gribben JG
    J Immunol Methods; 2009 Aug; 348(1-2):95-100. PubMed ID: 19576900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein.
    Guenova M; Balatzenko G
    Hematology; 2008 Jun; 13(3):137-41. PubMed ID: 18702870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia.
    Retnakumari A; Jayasimhan J; Chandran P; Menon D; Nair S; Mony U; Koyakutty M
    Nanotechnology; 2011 Jul; 22(28):285102. PubMed ID: 21654031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
    Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
    Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
    Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
    Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow.
    Ashman LK; Cambareri AC; To LB; Levinsky RJ; Juttner CA
    Blood; 1991 Jul; 78(1):30-7. PubMed ID: 1712644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.